Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-12
2007-06-12
Navarro, Mark (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388200, C530S388400, C530S389500, C424S130100, C424S141100, C424S150100, C435S007100
Reexamination Certificate
active
11171085
ABSTRACT:
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically toP. aeruginosamucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy ofP. aeruginosainfection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains ofP. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
REFERENCES:
patent: 4578458 (1986-03-01), Pier et al.
patent: 4902616 (1990-02-01), Fournier et al.
patent: 5055455 (1991-10-01), Pier
patent: 5233024 (1993-08-01), Schreiber et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5407796 (1995-04-01), Cutting et al.
patent: 5434086 (1995-07-01), Collins et al.
patent: 5502039 (1996-03-01), Pier
patent: 5589591 (1996-12-01), Lewis et al.
patent: 5980910 (1999-11-01), Pier
patent: 5989542 (1999-11-01), Pier et al.
patent: 6245735 (2001-06-01), Pier
patent: 6399066 (2002-06-01), Pier
patent: 6743431 (2004-06-01), Pier
patent: 6825178 (2004-11-01), Pier et al.
patent: 2002/0009457 (2002-01-01), Bowersock et al.
patent: 2002/0119166 (2002-08-01), Pier et al.
patent: 2003/0124631 (2003-07-01), Pier et al.
patent: 2004/0091494 (2004-05-01), Pier
patent: 0 120 532 (1984-10-01), None
patent: WO 91/02796 (1991-03-01), None
patent: WO 92/18162 (1992-10-01), None
patent: WO 93/12240 (1993-06-01), None
patent: WO 93/17040 (1993-09-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 94/04669 (1994-03-01), None
patent: WO 94/04671 (1994-03-01), None
patent: WO 94/08617 (1994-04-01), None
patent: WO 94/25607 (1994-11-01), None
patent: WO 95/06743 (1995-03-01), None
patent: WO 95/13365 (1995-05-01), None
patent: WO 95/25796 (1995-09-01), None
patent: WO 95/28494 (1995-10-01), None
patent: WO 02/94854 (2002-11-01), None
GENBANK Submission; NIH/NCBI; Accession No. M28668; Riordan; Dec. 15, 1989 (last submission). (Previously cited as Riordan et al.)
Albus et al., Increased levels of IgG subclasses specific forPseudomonas aeruginosaexoenzyme and polysaccharide antigens in chronically infected patients with cystic fibrosis. APMIS. Dec. 1989;97(12):1146-8.
Bougher et al., Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Hum Gene Ther. May 1994;5(5):615-39.
Boyer et al., Poster Presentation. American Thoracic Society, #D33, May 17, 2002.
Cheng et al., Immunoglobulin A antibodies againstPseudomonas aeruginosain the tear fluid of contant lens wearers. Invest Ophthalmol Vis Sci. Sep. 1996;37(10):2081-8.
Ciofu et al., Aviditiy of anti-P aeruginosaantibodies during chronic infection in patients with cystic fibrosis. Thorax. Feb. 1999;54(2):141-4.
Davies et al., Reduction in the adherence ofPseudomonas aeruginosato native cystic fibrosis epithelium with anti-asialoGMI antibody and neuraminidase inhibition. Eur Respir J. Mar. 1999;13(3):565-70.
De Kievit et al., Monoclonal antibodies that distinguish inner core, outer core, and lipid A regions ofPseudomonas aeruginosalipopolysaccharide. J Bacteriol. Dec. 1994;176(23):7129-39.
DesJardins et al., Abstracts from the annual meeting. Am Soc Microbiol. 1989; p. 49 (abstract B-110).
Garner et al., Immunogenic properties ofPseudomonas aeruginosamucoid exopolysaccharide. Infect Immun. Jun. 1990;58(6):1835-42.
Imundo et al., Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A. Mar. 28, 1995;92(7):3019-23.
Irvin et al., Immunochemical examination ofPseudomonas aeruginosaglycocalyx: a monoclonal antibody which recognizes L-guluronic acid residues of alginic acid. Can J Microbiol. Mar. 1985;31(3):268-75.
Johansen et al., Experimental immunization withPseudomonas aeruginosaalginate induces IgA and IgG antibody responses. APMIS. Dec. 1991;99(12):1061-8.
Kropinski et al., The extraction and analysis of lipopolysaccharide fromPseudomonas aeruginosastrain PAO, and three rough mutants. Can J Microbiol. Mar. 1979;25(3):390-8.
Mai et al., Inhibition of adherence of mucoidPseudomonas aeruginosaby alginase, specific monoclonal antibodies, and antibiotics. Infect Immun. Oct. 1993;61(10):4338-43.
Mai et al., Suppression of lymphocyte and neutrophil functions byPseudomonas aeruginosamucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments. Infect Immun. Feb. 1993;61(2):559-64.
Masoud et al., General strategy for structural analysis of the oligosaccharide region of lipooligosaccharides. Structure of the oligosaccharide componentPseudomonas aeruginosaIATS serotype 06 mutant R5 rough-type lipopolysaccharide. Biochemistry. Sep. 6, 1994;33(35):10568-78.
Masoud et al., Structural elucidation of the lipopolysaccharide core region of the O-chain-deficient mutant strain A28 fromPseudomonas aeruginosaserotype 06 (International Antigenic Typing Scheme). J Bacteriol. Dec. 1995;177(23):6718-26.
Meluleni et al., MucoidPseudomonas aeruginosagrowing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol. Aug. 15, 1995;155(4):2029-38.
Meluleni et al., 94th General Meeting of the American Society for Microbiology, Las Vegas, Nevada, May 23-27, 1994. Abst Annu Meet Am Soc Microbiol. May 1994; 94(0): 160.
Middleton et al., Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth. Eur Respir J. Mar. 1994;7(3):442-5.
Parad et al., Pulmonary outcome in cystic fibrosis is influenced primarily by muciodPseudomonas aeruginosainfection and immune status and only modestly by genotype. Infect Immun. Sep. 1999;67(9):4744-50.
Pennington et al.,Type-specificvs.cross-protective vaccination for gram-negative bacterial pneumonia. J Infect Dis. Dec. 1981;144(6):599-603.
Pier et al., Opsonophagocytic killing antibody toPseudomonas aeruginosamucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N Engl J Med. Sep. 24, 1987;317(13):793-8.
Pier et al., Protection against mucoidPseudomonas aeruginosain rodent models of endobronchial infections. Science. Aug. 3, 1990;249(4968):537-40.
Pier et al., Human immune response toPseudomonas aeruginosamucoid exopolysaccharide (alginate) vaccine. Infect Immun. Sep. 1994;62(9):3972-9.
Pier et al., Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science. Jan. 5, 1996;271(5245)64-7.
Pier et al., Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance ofPseudomonas aeruginosafrom the lung. Proc Natl Acad Sci U S A. Oct. 28, 1997;94(22):12088-93.
Pier et al.,Salmonella typhiuses CFTR to enter intestinal epithelial cells. Nature. May 7, 1998;393(6680):79-82.
Pier et al., Complement deposition by antibodies toPseudomonas aeruginosamucoid exopolysaccharide (MEP) and by non-MEP specific opsonins. J Immunol. Sep. 15, 1991;147(6):1869-76.
Pier et al., Analysis of naturally occuring antibodies to mucoidPseudomonas aeruginosain cystic fibrosis patients. J Infect Dis. Feb. 1996;173(2):513-5.
Pier et al., Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody toPseudomonas aeruginosa. J Clin Invest. Mar. 1993;91(3):1079-87.
Pier et al., Vaccine potentialPseudomonas aeruginosamucoid exopolysaccharide (alginate). Antibiot Chemother. 1991;44:136-42. Review.
Pollack et al., Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies toPseudomonas aeruginosalipopolysaccharide. Infect Immun. Nov. 1995;63(11):4481-8.
Pressler et al., Immunoglobulin allotypes and IgG subclass antibody response toPseudomonas aeruginosaantigens in chronically infected cystic fibrosis patients. Clin Exp Immuno
Cavacini Lisa
Pier Gerald B.
Posner Marshall R.
Preston Michael J.
Beth Israel Deaconess Medical Center Inc.
Brigham & Women's Hospital Inc.
Navarro Mark
Wolf Greenfield & Sacks PC
LandOfFree
P. aeruginosa mucoid exopolysaccharide specific binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P. aeruginosa mucoid exopolysaccharide specific binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P. aeruginosa mucoid exopolysaccharide specific binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3874499